All-Cause 30-Day Mortality After Surgical Treatment for Head and Neck Squamous Cell Carcinoma in the United States

2019 ◽  
Vol 42 (7) ◽  
pp. 596-601 ◽  
Author(s):  
Aleksandr R. Bukatko ◽  
Parth B. Patel ◽  
Vindhya Kakarla ◽  
Matthew C. Simpson ◽  
Eric Adjei Boakye ◽  
...  
2019 ◽  
Vol 31 (3) ◽  
pp. 138-145 ◽  
Author(s):  
Alexandre Bozec ◽  
Dorian Culié ◽  
Gilles Poissonnet ◽  
Olivier Dassonville

2019 ◽  
Vol 22 ◽  
pp. S65
Author(s):  
A. Berger ◽  
M. Contente ◽  
N. Kumar ◽  
P. Abraham ◽  
R. Shah ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17554-e17554
Author(s):  
Matthew Gaubatz ◽  
Aleksandr R Bukatko ◽  
Katherine M. Polednik ◽  
Matthew C Simpson ◽  
Eric Adjei Boakye ◽  
...  

e17554 Background: There has been a shift in the epidemiologic landscape of head and neck cancer (HNC) with decreasing incidence of tobacco-related and increasing incidence of human papillomavirus (HPV)-related HNC. While it is often reported that ≥ 90% of HNC is considered squamous cell carcinoma (SCC), there is an apparent lack of recent population-based data to support this claim. This study aimed to estimate the current proportion and evaluate change in the proportion of SCC in HNC diagnoses in North America (United States and Canada) from 1995 to 2015. Methods: We queried the North American Association of Central Cancer Registries (NAACCR) database for HNC cases that were of either squamous (SQ) (ICD-0-3: 8050-8089) or squamous plus unspecified epithelial (SQE) (ICD-0-3:8010-8089) origin in the United States and Canada ( n = 1,054,409). All HNC included in the analysis were microscopically confirmed, malignant head and neck primary tumor sites of the oral cavity, nasopharynx, hypopharynx, oropharynx, nasal cavity, and larynx. Sub-analyses were conducted across more extensive cohort restriction combinations (country specific, registry specific, and primary sequence of cancer). Results: The overall proportion of SCC in HNC in North America from 1995-2015 was 81.7% (95% CI: 81.7 – 81.8) for SQ and 84.9% (95% CI: 84.8 – 85.0) for SQE. The proportion of SCC in HNC peaked in 2015 with 83.3% (95% CI: 83.0 – 83.6) for SQ and 85.9% (95% CI: 85.6 – 86.2) for SQE; and was lowest in 2005 with 80.7% (95% CI: 80.4 – 81.1) for SQ and 84.3% (95% CI: 83.9 – 84.6) for SQE. In the time period of this study (1995 – 2015), there were no years for which SQ or SQE made up 90% or more of HNC for any of the HNC cohorts. Conclusions: The changing landscape of HNC risk factors in the United States and Canada warrants re-evaluation and update of HNC epidemiological literature with regards to the proportion of SCC in HNC.


2014 ◽  
Vol 128 (6) ◽  
pp. 552-554 ◽  
Author(s):  
M Adams ◽  
R Caffrey

AbstractBackground:Coincident thyroid and head and neck squamous cell carcinomas are rare. This paper presents a case of synchronous laryngeal squamous cell carcinoma, follicular thyroid carcinoma and micropapillary thyroid carcinoma.Methods:A PubMed search was performed for articles describing synchronous thyroid and head and neck squamous cell carcinomas, using the search terms ‘thyroid cancer’, ‘cancer of the head and neck’, ‘synchronous’ and ‘synchronous neoplasm’.Results:The literature suggests that the head and neck squamous cell carcinoma stage is a better predictor of outcome than the extent of surgical treatment of the thyroid gland in synchronous malignancies.Conclusion:The decision regarding surgical treatment of the thyroid in synchronous thyroid and head and neck squamous cell carcinomas should take several factors into account. The head and neck squamous cell carcinoma stage is the strongest predictor of outcome, although patient-related factors and the location of malignant thyroid tissue may also affect management.


Sign in / Sign up

Export Citation Format

Share Document